Related Articles
Before March 2017, doctors at Cancer Institute of Guyana (CIG, Georgetown, Guyana, South America) assumed that once their patients with cervical cancer completed a course of external beam radiation therapy (EBRT) they would seek out intracavitary high dose rate (HDR) brachytherapy boost, the recommended next step in treating the disease….
The GEC-ESTRO phase III clinical trial comparing accelerated partial breast irradiation (APBI) and whole breast irradiation (WBI) has shown that APBI with multicatheter interstitial brachytherapy is associated with significantly fewer grade 2-3 late skin side effects and equivalent cosmesis compared to WBI plus boost treatment. These latest results from the GEC-ESTRO study data were presented…
Nice University’s Head of Radiation Therapy Department, Jean-Michel Hannoun-Levi, MD, PhD, has been involved in brachytherapy as far back as his first days as a radiation oncology resident at Leon Berard (Lyon) and Alexis Vautrin (Nancy) Cancer Centers, and has been fortunate to meet and work with renowned French brachytherapists Monique Pernot, Alain Gerbaulet and…
Women with primary vaginal cancer (PVC) who received brachytherapy – either by itself or in combination with external beam radiation therapy (EBRT) – had higher median overall survival (6.1 years) versus patients who received EBRT alone (3.6 years). The results were from a Surveillance, Epidemiology, and End Result (SEER) database study of 2,517 vaginal cancer…
Women with gynecological cancers in Davao, an island in the south of the Philippines, now have convenient access to potentially curative brachytherapy treatment. On March 23, doctors at The Cancer Center for Mindanao (Davao Regional Medical Center, Barangay Apokon, Tagum City) used their Elekta microSelectron® afterloader to deliver intracavitary brachytherapy to their first patient, a…
The hospitals and care centers comprising the Willis-Knighton health system (Shreveport-Bossier, Louisiana, USA) constitute a critical healthcare resource for local residents and patients throughout Southern Arkansas, East Texas and North Louisiana, a combined catchment area of about one million people. The only locally owned, locally operated not-for-profit health system in Shreveport-Bossier, Willis-Knighton is committed to…
As a leading innovator of precision radiation therapy solutions, Elekta is committed to ensuring that every patient has access to the best cancer care possible.
The products and product clinical indications for use described within FOCUS may not have clearance or registration in certain countries. Please consult Elekta in your country for questions concerning a product or clinical use subject. This site may contain information provided by third party sources to Elekta that does not necessarily represent the views of Elekta. Individuals interviewed provided information based on their personal experience and were not compensated for their participation. Accordingly, third party information contained in this site is provided "as is" with no guarantees of completeness, accuracy, usefulness, or timeliness.
© 2022 Elekta | FOCUS Magazine. | Privacy Policy | Cookies
